- Home
- KIM vs MRNA Comparison
KIM vs MRNA Comparison
Compare KIM & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIM
- MRNA
- Stock Information
- Founded
- KIM 1958
- MRNA 2010
- Country
- KIM United States
- MRNA United States
- Employees
- KIM N/A
- MRNA N/A
- Industry
- KIM Real Estate Investment Trusts
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KIM Real Estate
- MRNA Health Care
- Exchange
- KIM Nasdaq
- MRNA Nasdaq
- Market Cap
- KIM 14.4B
- MRNA 16.0B
- IPO Year
- KIM 1991
- MRNA 2018
- Fundamental
- Price
- KIM $20.13
- MRNA $34.30
- Analyst Decision
- KIM Buy
- MRNA Hold
- Analyst Count
- KIM 16
- MRNA 20
- Target Price
- KIM $24.28
- MRNA $55.53
- AVG Volume (30 Days)
- KIM 4.6M
- MRNA 12.7M
- Earning Date
- KIM 05-01-2025
- MRNA 05-01-2025
- Dividend Yield
- KIM 4.99%
- MRNA N/A
- EPS Growth
- KIM N/A
- MRNA N/A
- EPS
- KIM 0.55
- MRNA N/A
- Revenue
- KIM $2,037,014,000.00
- MRNA $3,236,000,000.00
- Revenue This Year
- KIM N/A
- MRNA N/A
- Revenue Next Year
- KIM $3.24
- MRNA $23.65
- P/E Ratio
- KIM $36.45
- MRNA N/A
- Revenue Growth
- KIM 14.22
- MRNA N/A
- 52 Week Low
- KIM $17.57
- MRNA $29.25
- 52 Week High
- KIM $25.83
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- KIM 28.94
- MRNA 49.35
- Support Level
- KIM $20.44
- MRNA $32.62
- Resistance Level
- KIM $21.79
- MRNA $37.91
- Average True Range (ATR)
- KIM 0.53
- MRNA 2.41
- MACD
- KIM -0.11
- MRNA 0.46
- Stochastic Oscillator
- KIM 4.53
- MRNA 56.44
About KIM Kimco Realty Corporation (HC)
One of the oldest real estate investment trusts in the United States, Kimco Realty owns interests in 569 shopping centers throughout major markets in the US, representing roughly 87 million square feet.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.